Clicky

Brainstorm Cell Therapeutics Inc.(BCLI)

Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company's NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.


Keywords: Biotechnology Biology Stem Cell Parkinson's Disease Bone Multiple Sclerosis Medical Research Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Neurochemistry Degenerative Disease Bone Marrow Induced Stem Cells Mesenchymal Stem Cell Neurodegenerative Disorders Adult Stem Cell Storm Stem Cell Therapies Cell Product Cell Encapsulation Neuron Vascular Endothelial Growth Factor Growth Factor Hadassah Medical Center

Home Page: www.brainstorm-cell.com

BCLI Technical Analysis

1325 Avenue of Americas
New York, NY 10019
United States
Phone: 201 488 0460


Officers

Name Title
Mr. Chaim Lebovits Chief Exec. Officer
Dr. Irit Arbel DSc, Ph.D. Co-Founder & Independent Vice Chair of the Board
Dr. Ralph Z. Kern Pres & Chief Medical Officer
Dr. Stacy R. Lindborg Ph.D. Exec. VP & Chief Devel. Officer
Mr. Uri Yablonka Exec. VP, Chief Bus. Officer, Sec. & Director
Ms. Alla Patlis CPA, M.B.A. Controller & Interim CFO
Dr. David Setboun M.B.A., Pharm.D. Exec. VP & COO
Dr. Yael Gothelf VP of Scientific & Regulatory Affairs
Ms. Antal Pearl-Lendner VP & Chief Legal Counsel
Dr. Daniel Offen Ph.D. Chief Scientific Advisor

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 47.3885
Price-to-Sales TTM: 0
IPO Date: 2003-08-28
Fiscal Year End: December
Full Time Employees: 43
Back to stocks